2008, Number 1
<< Back
Med Sur 2008; 15 (1)
The most significant advances in the understanding of cancer in 2007
Baptista GHA
Language: Spanish
References: 10
Page: 46-49
PDF size: 77.66 Kb.
Text Extraction
No abstract
REFERENCES
Saslow D et al. American Cancer Society guidelines for breast screening with MRIas an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89.
Ehman C et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356: 1295-1303.
Kuhl CK et al. Magnetic resonance imaging versus mammography for diagnosing ductal carcinoma in situ. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; June 2007; Chicago, IL.
Khul CK et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007; 370: 485-492.
Glass AG et al. Breast cancer incidence, 1980–2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1161.
Avdin PM et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-4.
Ewar JA et al. Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; June 2007; Chicago, IL.
Powell et al. Consolidation with arsenic trioxide (As2O3) significantly improves event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. Presented at the 43rd Annual Meeting of the Society of Clinical Oncology; June 2007; Chicago, IL.
Atallah EL et al. Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; June 2007; Chicago, IL.
Richardson PG et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Presented at the 48th Annual Meeting of American Society of Hematology; December 2006; Orlando, FL.
Full text